Humana Inc. (HUM) Price Target Increased to $255.00 by Analysts at Oppenheimer Holdings, Inc.
Humana Inc. (NYSE:HUM) had its price target lifted by Oppenheimer Holdings, Inc. from $236.00 to $255.00 in a report released on Thursday. Oppenheimer Holdings, Inc. currently has an outperform rating on the insurance provider’s stock. Oppenheimer Holdings also issued estimates for Humana’s Q3 2017 earnings at $3.18 EPS, FY2017 earnings at $11.55 EPS and FY2018 earnings at $12.20 EPS.
A number of other analysts have also recently weighed in on HUM. UBS AG reissued a neutral rating and set a $237.00 target price (up from $205.00) on shares of Humana in a report on Wednesday, June 28th. Zacks Investment Research cut shares of Humana from a hold rating to a sell rating in a report on Thursday, July 27th. BidaskClub cut shares of Humana from a hold rating to a sell rating in a report on Monday, July 31st. Piper Jaffray Companies increased their target price on shares of Humana to $280.00 and gave the stock an overweight rating in a report on Thursday. Finally, Cowen and Company reaffirmed a buy rating and issued a $230.00 price objective on shares of Humana in a report on Friday, July 14th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The company has an average rating of Hold and an average price target of $241.65.
Humana (NYSE:HUM) last issued its earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.08 by $0.41. The company had revenue of $13.53 billion for the quarter, compared to analysts’ expectations of $13.61 billion. Humana had a net margin of 3.37% and a return on equity of 15.85%. During the same period in the prior year, the company earned $2.30 earnings per share.
In other news, VP Heidi S. Margulis sold 1,500 shares of the firm’s stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $231.96, for a total transaction of $347,940.00. Following the completion of the transaction, the vice president now owns 8,150 shares in the company, valued at approximately $1,890,474. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Brian P. Leclaire sold 4,971 shares of the firm’s stock in a transaction dated Wednesday, June 28th. The shares were sold at an average price of $240.00, for a total transaction of $1,193,040.00. Following the transaction, the senior vice president now owns 14,258 shares of the company’s stock, valued at approximately $3,421,920. The disclosure for this sale can be found here. Company insiders own 0.80% of the company’s stock.
Several institutional investors have recently bought and sold shares of the stock. BlackRock Inc. raised its position in Humana by 2,281.7% in the first quarter. BlackRock Inc. now owns 12,387,144 shares of the insurance provider’s stock valued at $2,553,487,000 after buying an additional 11,867,056 shares during the period. FMR LLC raised its position in Humana by 57.9% in the first quarter. FMR LLC now owns 5,050,853 shares of the insurance provider’s stock valued at $1,041,184,000 after buying an additional 1,851,197 shares during the period. Renaissance Technologies LLC raised its position in Humana by 84.3% in the first quarter. Renaissance Technologies LLC now owns 2,691,700 shares of the insurance provider’s stock valued at $554,867,000 after buying an additional 1,231,400 shares during the period. Wellington Management Group LLP raised its position in Humana by 2,651.1% in the first quarter. Wellington Management Group LLP now owns 775,755 shares of the insurance provider’s stock valued at $159,915,000 after buying an additional 747,557 shares during the period. Finally, AQR Capital Management LLC raised its position in Humana by 413.8% in the first quarter. AQR Capital Management LLC now owns 736,019 shares of the insurance provider’s stock valued at $151,723,000 after buying an additional 592,772 shares during the period. Institutional investors own 99.66% of the company’s stock.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.